Article thumbnail

VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease

By Tonya N. Taylor, W. Michael Caudle and Gary W. Miller


Dopamine is transported into synaptic vesicles by the vesicular monoamine transporter (VMAT2; SLC18A2). Disruption of dopamine storage has been hypothesized to damage the dopamine neurons that are lost in Parkinson's disease. By disrupting vesicular storage of dopamine and other monoamines, we have created a progressive mouse model of PD that exhibits catecholamine neuron loss in the substantia nigra pars compacta and locus coeruleus and motor and nonmotor symptoms. With a 95% reduction in VMAT2 expression, VMAT2-deficient animals have decreased motor function, progressive deficits in olfactory discrimination, shorter latency to behavioral signs of sleep, delayed gastric emptying, anxiety-like behaviors at younger ages, and a progressive depressive-like phenotype. Pathologically, the VMAT2-deficient mice display progressive neurodegeneration in the substantia nigra (SNpc), locus coeruleus (LC), and dorsal raphe (DR) coupled with α-synuclein accumulation. Taken together, these studies demonstrate that reduced vesicular storage of monoamines and the resulting disruption of the cytosolic environment may play a role in the pathogenesis of parkinsonian symptoms and neurodegeneration. The multisystem nature of the VMAT2-deficient mice may be useful in developing therapeutic strategies that go beyond the dopamine system

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1992). A cDNA that suppresses MPP toxicity encodes a vesicular amine transporter,”
  2. (1993). A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies
  3. (2002). A simple method to measure stride length as an index of nigrostriatal dysfunction in mice,”
  4. An Essay on the Shaking Palsy,
  5. (1997). andR.H.Edwards,“Vesiculartransportregulatesmonoamine storage and release but is not essential for amphetamine action,”
  6. (1986). ATP-driven H pumping into intracellular organelles,”
  7. (2006). C o l e b r o o k e ,T .H u m b y ,P .J .L y n c h ,D .P .M c G o w a n ,J . Xia,andP.C.Emson,“Age-relateddeclineinstriataldopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson’s disease,”
  8. (2002). Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice,”
  9. (1992). D o t y ,M .B .S t e r n ,C .P f e i
  10. (2004). Dbh(-/-) mice are hypotensive, have altered circadian rhythms, and have abnormal responses to dieting and stress,”
  11. (2001). Deletion of the alphasynuclein locus in a subpopulation of C57BL/6J inbred mice,”
  12. (2004). Depression and Parkinson’s disease,”
  13. (2002). Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,”
  14. (2007). Differential gene expression in the striatum of mice with very low expression of the vesicular monoamine transporter type 2 gene,”
  15. (1992). E r i c k s o n ,L .E .E i d e n ,a n dB .J .H o ffman, “Expression cloning of a reserpine-sensitive vesicular monoamine transporter,”
  16. (1954). E.D.Freis,“Mentaldepressioninhypertensivepatientstreated for long periods with large doses of reserpine,” The New England
  17. (1999). Etiology and pathogenesis of Parkinson’s disease,”
  18. (2002). Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson’s diseaseassociation,”
  19. (2006). Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinsondiseaseinwomen,”
  20. (2005). Hodara et al., “Reversible inhibition of α-synuclein fibrillization by dopaminochromemediated conformational alterations,”
  21. (1998). Hypothesis: the role of dopaminergic transporters inselectivevulnerabilityofcellsinParkinson’sdisease,”
  22. (1999). Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson’s disease,”
  23. (1999). Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice,”
  24. (1998). Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice,”
  25. (2005). Increased vulnerability to L-DOPA toxicity in dopaminergic neurons from VMAT2 heterozygote knockout mice,”
  26. (2008). Inhibition of vesicular monoamine
  27. (1998). Iodine-123-N-ω-fluoropropyl-2/β-carbomethoxy3β-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease,”
  28. (1993). K i l b o u r n ,J .N .D a S i l v a ,K .A .F r e y ,R .A .K o e p p e
  29. (2001). Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct,”
  30. (1997). Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine,”
  31. (2006). Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice,”
  32. M.Saito,M.Maruyama,K.Ikeuchietal.,“Autosomalrecessive juvenile parkinsonism,” Brain and Development,
  33. (2001). Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism,” Molecular and Cellular Biology,
  34. (2004). Neurodegeneration and neuroprotection in Parkinson disease,”
  35. (1990). New developments in the pathology of Parkinson’s disease,”
  36. (2007). Non-motor dysfunction
  37. (2009). Nonmotor symptoms of Parkinson’s disease revealed in an animal model with reduced monoamine storage capacity,”
  38. (2007). Norepinephrine: the redheaded stepchild of Parkinson’s disease,”
  39. (2007). Olfactory dysfunction in Parkinson’s disease,”
  40. (1983). Olfactory impairment in Parkinson’s disease,”
  41. (2006). osharov ,R.G.W .Staal,J .Bov´ eetal.,“α-Synucleinoverexpression increases cytosolic catecholamine concentration,”
  42. (1978). Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones,”
  43. (2003). Parkinson’s disease: mechanisms and models,”
  44. (2002). Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein,”
  45. (2003). Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2(
  46. (2010). Progressive noradrenergic degeneration precedes nigral cell loss in a mouse model of Parkinson’s disease,”
  47. (2002). R e v e r o n ,K .V .S a v e l i e v a l ,J .L .T i l l e r s o n
  48. (2007). Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration,”
  49. (1954). Reserpine antagonism of morphine analgesia in mice,”
  50. (2003). Staging of brain pathology related
  51. (2002). Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages),”
  52. (2004). Structural conservation in the major facilitator superfamily as revealed by comparative modeling,”
  53. (1989). Structure and function of vacuolar class of ATPdrivenprotonpumps,”PhysiologicalReviews,v ol.69,no .3,pp .
  54. (1997). Symptoms and duration of the prodromal phase in Parkinson’s disease,”
  55. (1994). The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors,”
  56. (2006). The Parkinson’s complex: parkinsonism is j u s tt h et i po ft h eI c e b e r g ,
  57. (2006). The pathogenesis of cell death in Parkinson’s disease,”
  58. (1997). The role of vesicular transport proteins in synaptic transmission and neural degeneration,”
  59. (2004). The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine,”
  60. (1995). Vesicular neurotransmitter transporters: from bacteria to humans,”
  61. Vmat2 heterozygous mutant mice display a depressive-like phenotype,” JournalofNeuroscience,vol.27,no.39,pp.10520–10529,2007.
  62. (1997). VMAT2 knockout mice: heterozygotes display reduced amphetamineconditionedreward,enhanced amphetaminelocomotion,and enhancedMPTPtoxicity,”ProceedingsoftheNationalAcademy of